Eli Lilly and Company $LLY is Generali Investments Management Co LLC’s 9th Largest Position

Generali Investments Management Co LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 17.5% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,220 shares of the company’s stock after acquiring an additional 1,521 shares during the period. Eli Lilly and Company comprises about 2.7% of Generali Investments Management Co LLC’s portfolio, making the stock its 9th largest position. Generali Investments Management Co LLC’s holdings in Eli Lilly and Company were worth $12,258,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the business. E. Ohman J or Asset Management AB raised its holdings in shares of Eli Lilly and Company by 137.4% in the 2nd quarter. E. Ohman J or Asset Management AB now owns 65,270 shares of the company’s stock valued at $78,287,000 after purchasing an additional 37,773 shares in the last quarter. Spinnaker Investment Group LLC boosted its stake in shares of Eli Lilly and Company by 65.4% during the second quarter. Spinnaker Investment Group LLC now owns 473 shares of the company’s stock valued at $568,000 after purchasing an additional 187 shares in the last quarter. A&I Financial Services LLC purchased a new position in Eli Lilly and Company during the second quarter valued at approximately $239,000. Carolina Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 1.5% during the second quarter. Carolina Wealth Advisors LLC now owns 1,724 shares of the company’s stock valued at $2,068,000 after buying an additional 25 shares during the period. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors raised its stake in Eli Lilly and Company by 1.7% in the second quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 5,083 shares of the company’s stock worth $6,097,000 after buying an additional 83 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY opened at $1,230.00 on Tuesday. The company has a market cap of $1.16 trillion, a P/E ratio of 41.28, a price-to-earnings-growth ratio of 1.38 and a beta of 0.51. The company has a quick ratio of 1.00, a current ratio of 1.35 and a debt-to-equity ratio of 1.41. The firm’s 50-day moving average price is $1,162.38 and its 200-day moving average price is $1,048.95. Eli Lilly and Company has a 52-week low of $625.90 and a 52-week high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last released its earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. The company had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. Eli Lilly and Company’s revenue for the quarter was up 47.7% on a year-over-year basis. During the same period last year, the business earned $6.31 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. As a group, equities analysts anticipate that Eli Lilly and Company will post 36.77 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. The ex-dividend date is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 23.22%.

Eli Lilly and Company News Roundup

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The U.K. Medicines and Healthcare products Regulatory Agency approved Lilly’s Foundayo for weight loss and weight maintenance in certain adults with obesity or overweight-related health conditions. The authorization is the pill’s first European approval and gives Lilly access to a large potential market supported by its global commercial infrastructure. Eli Lilly’s GLP-1 Pill Secures First European Milestone
• Positive Sentiment: The approval also strengthens Lilly’s competitive position against Novo Nordisk in obesity drugs. Analysts and investors are increasingly focused on whether a convenient oral treatment can expand the GLP-1 market and increase patient adoption. Why Eli Lilly Topped the Market Today
• Positive Sentiment: Lilly’s latest quarterly performance remains a major support for the stock. Second-quarter revenue rose 47.7% year over year to approximately $23.0 billion, while adjusted EPS of $8.38 exceeded the $6.40 consensus estimate. Management set fiscal 2026 EPS guidance of $35.50 to $36.50, highlighting continued confidence in demand for its portfolio. Eli Lilly Posts Blowout Growth and Raises Its Outlook
• Neutral Sentiment: Investors are also weighing potential U.S. policies encouraging domestic pharmaceutical manufacturing. Lilly may be relatively well positioned if reshoring requirements favor companies with significant U.S. production capacity, although the policy details and costs remain uncertain. Eli Lilly vs. Novo Nordisk
• Neutral Sentiment: Sector rotation toward innovative healthcare companies, as investors seek alternatives to highly valued technology stocks, provided an additional supportive backdrop for Lilly. Jim Cramer Highlights Pharmaceutical Giants
• Negative Sentiment: Executive Vice President Anat Hakim sold 5,000 shares worth approximately $5.95 million under a pre-arranged Rule 10b5-1 trading plan. The transaction may attract attention, but its scheduled nature reduces its significance as a signal about Lilly’s outlook. SEC Form 4 Filing

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Bank of America upped their target price on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a report on Friday, July 10th. Royal Bank Of Canada boosted their price target on Eli Lilly and Company from $1,250.00 to $1,500.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 8th. The Goldman Sachs Group restated a “buy” rating and set a $1,283.00 price objective on shares of Eli Lilly and Company in a research note on Friday, May 22nd. Sanford C. Bernstein raised their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the company an “outperform” rating in a research report on Tuesday, July 14th. Finally, Barclays lifted their target price on Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the company an “overweight” rating in a research note on Monday, May 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,292.18.

Insider Buying and Selling at Eli Lilly and Company

In other news, EVP Anat Hakim sold 5,000 shares of the business’s stock in a transaction on Friday, August 7th. The shares were sold at an average price of $1,190.00, for a total transaction of $5,950,000.00. Following the sale, the executive vice president directly owned 11,875 shares of the company’s stock, valued at $14,131,250. The trade was a 29.63% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.14% of the stock is owned by company insiders.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.